Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that it will host a key opinion leader (KOL) call discussing the treatment of Epstein-Barr virus (EBV)-associated lymphoma on Friday, June 5th at 12 P.M. Eastern Time. Read More

Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that the Company recently held a collaborative and productive guidance (Type C) Meeting with the United States Food and Drug Administration (FDA). Read More

Viracta Announces Appointment of Lisa Rojkjaer, MD, as Chief Medical Officer

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Lisa Rojkjaer, MD, as Chief Medical Officer (CMO), effective May 1, 2020. Read More

Events

June 5, 2020

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma Read More

February 25-27, 2020

Biocom's 10th Annual Global Life Science Partnering Conference, in La Jolla, CA Read More

February 20, 2020

16th Annual UCSD Moores Cancer Center Symposium, in San Diego, CA Read More

Recent News

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that it will host a key opinion leader (KOL) call discussing the treatment of Epstein-Barr virus (EBV)-associated lymphoma on Friday, June 5th at 12 P.M. Eastern Time. Read More

Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that the Company recently held a collaborative and productive guidance (Type C) Meeting with the United States Food and Drug Administration (FDA). Read More

Viracta Announces Appointment of Lisa Rojkjaer, MD, as Chief Medical Officer

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Lisa Rojkjaer, MD, as Chief Medical Officer (CMO), effective May 1, 2020. Read More

Events

June 5, 2020

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma Read More

February 20, 2020

16th Annual UCSD Moores Cancer Center Symposium, in San Diego, CA Read More

February 25-27, 2020

Biocom's 10th Annual Global Life Science Partnering Conference, in La Jolla, CA Read More